Plus more appointments in contract pharma in this week's column.
Ergomed, a British drug development services company, has appointed Rolf Stahel to its board as a non-executive Chairman. Stahel was also recently made non-executive Chairman of Midatech , a UK company which uses gold nanoparticles for drug delivery.
The pharmaceutical veteran was CEO of Shire between 1994 and 2003, a tenure during which he oversaw six mergers and acquisitions. Prior to this, he worked for 27 years at Wellcome, where he rose to Director of Group Marketing, covering R&D portfolio decisions. Stahel also sits on the advisory board of Imperial Business School at Imperial College, London.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.
In an Outsourcing-Pharma sporting special, we reveal why GSK will not be at the Rio Olympics, why...
This week's round-up of who's going places in contract research, manufacturing and services.
The latest faces in drug discovery, CROs, and research charities.